Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Pucotenlimab in Platinum-intolerant Advanced HNSCC
NCT07628855Phase 2Not yet recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Primary completion
- Aug 2028
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Planned start May 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07628855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628855.